Biogen (BIIB) reported Q4 non-GAAP earnings Wednesday of $3.44 per diluted share, up from $2.95 a year earlier.

Analysts polled by FactSet expected $3.35.

Revenue for the quarter ended Dec. 31 was $2.46 billion, up from $2.39 billion a year earlier.

Analysts surveyed by FactSet expected $2.41 billion.

The company said it expects fiscal 2025 non-GAAP EPS to fall in the range of $15.25 to $16.25.

Analysts polled by FactSet expect $16.33.

Biogen also said it expects fiscal 2025 revenue to decline by a mid-single-digit percentage year over year.

Analysts surveyed by FactSet expect revenue of $9.40 billion.